# Feasibility of FMISO in Brain Tumors

> **NCT03649880** · PHASE2 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 50 (estimated)

## Conditions studied

- Malignant Brain Neoplasm

## Interventions

- **DRUG:** ¹⁸F-Fluoromisonidazole
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Oxygen Therapy

## Key facts

- **NCT ID:** NCT03649880
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-06-01
- **Primary completion:** 2029-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03649880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03649880, "Feasibility of FMISO in Brain Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03649880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*